(Q58449069)

English

CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate

scientific article published on 09 August 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

based on heuristic

inferred from title

myeloid leukemia

1 reference

based on heuristic

inferred from title

chronic myeloid leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Alessandro Gozzetti

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Elisabetta Abruzzese

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

Bocchia M

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Ippoliti M

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Calabrese S

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Amabile M

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Pirrotta MT

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Crupi R

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Tozzuoli D

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Trawinska MM

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Defina M

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Martinelli G

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Lauria F

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

publication date

9 August 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

426-428

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404893

0 references

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404893

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404893

21 January 2018

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404893

21 January 2018

Punish the parent not the progeny.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404893

21 January 2018

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404893

21 January 2018

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404893

21 January 2018

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404893

21 January 2018

Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404893

21 January 2018

Identifiers

10.1038/SJ.LEU.2404893

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690698%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58449069&oldid=2157793268"